Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level

Hanna, C.R. , Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P. , Boyd, K.A. and Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, (doi: 10.1016/j.clon.2022.03.012) (PMID:35370039) (In Press)

[img] Text
267326.pdf - Published Version
Available under License Creative Commons Attribution.

407kB
[img] Text
267326Suppl.pdf - Supplemental Material

471kB

Abstract

Aims: The Short Course Oncology Treatment (SCOT) trial indicated that 3 months of adjuvant doublet chemotherapy was non-inferior to 6 months of treatment for patients with colorectal cancer, with considerably less toxicity. The SCOT trial results were disseminated in June 2017. The aim of this study was to understand if SCOT trial findings were implemented in Scotland. Materials and methods: A retrospective analysis was carried out on a dataset derived from a source population of 5.4 million people. Eligible patients were those with stage II or III colorectal cancer who received adjuvant chemotherapy. Logistic regression was applied to understand the extent of practice change to a 3-month adjuvant chemotherapy duration after the SCOT trial results were disseminated. Interrupted time series analysis was used to visualise differences in prescribing trends before and after June 2017 for the overall cohort, and by SCOT trial eligibility. Results: In total, 2310 patients were included in the study; 1957 and 353 treated pre- and post-June 2017, respectively. The median treatment duration decreased from 21 weeks (interquartile range 14–24) prior to June 2017 to 12 weeks (interquartile range 12–21 weeks) after June 2017 (P < 0.001). The proportion of patients receiving over 3 months of adjuvant treatment decreased from 75% to 42% (P < 0.001). This change was most noticeable for patients who met the SCOT trial eligibility criteria, and specifically for those with low-risk stage III disease and those treated with capecitabine and oxaliplatin (CAPOX). Although practice change occurred in all locations, there were differences between regions that could be explained by pre-SCOT trial prescribing trends. Discussion: A significant change in chemotherapy prescribing occurred after dissemination of the SCOT trial results. National, real-world data can be used to capture the extent of implementation of clinical trial results. In this case, implementation was aligned with clinical trial subgroup findings. This type of analysis could be conducted to evaluate the impact of other clinical trials.

Item Type:Articles
Additional Information:This study was funded by a CRUK Trials Fellowship grant awarded to C.R. Hanna (ID C61874/A2429), a CRUK grant ‘Creating a UK Colorectal Cancer Intelligence Hub’ (ID C23434/A23706) and a project specific grant awarded by the Beatson Cancer Charity (21-22-024), Glasgow.
Status:In Press
Refereed:Yes
Glasgow Author(s) Enlighten ID:McLoone, Mr Philip and Hanna, Catherine and Boyd, Dr Kathleen and Jones, Professor Robert
Authors: Hanna, C.R., Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P., Boyd, K.A., and Jones, R.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Public Health
Journal Name:Clinical Oncology
Publisher:Elsevier
ISSN:0936-6555
ISSN (Online):1433-2981
Published Online:31 March 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Clinical Oncology 2022
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
174279CRUK CTU Glasgow - Clinical Trial FellowshipCatherine HannaCancer Research UK (CRUK)C61974/A24293Institute of Cancer Sciences